• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:10:57 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    SC 13G/A 1 tv01198-johnsonjohnson.htm SCHEDULE 13G/A johnsonjohnson

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Johnson & Johnson

    Title of Class of Securities:  Common Stock

    CUSIP Number:  478160104

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  478160104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    4,272,484

    7.  SOLE DISPOSITIVE POWER

    216,472,293

    8.  SHARED DISPOSITIVE POWER

    11,473,811

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    227,946,104

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.66%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Johnson & Johnson

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    One Johnson & Johnson Plaza
    New Brunswick, New Jersey 08933

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    478160104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    227,946,104

      (b) Percent of Class:

    8.66%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  4,272,484

    (iii)  sole power to dispose of or to direct the disposition of:  216,472,293

    (iv)  shared power to dispose or to direct the disposition of:  11,473,811

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    10/5/2023$178.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded Johnson & Johnson from Outperform to Neutral and set a new price target of $150.00 from $160.00 previously

      7/23/24 6:31:28 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson expands efforts to champion the nursing workforce globally

      New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the global shortfall of nurses, which will reach approximately 4.5 million by 2030, driven in part by burnout and low morale, contributing to a signifi

      5/8/25 8:12:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

      Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.  Data from the QUASAR LTE

      5/5/25 8:05:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

      TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis  Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease   SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo acros

      5/5/25 8:05:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      1/30/24 12:46:49 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $JNJ
    SEC Filings

    See more
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:57:54 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director West Nadja

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:54:13 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      4/30/25 4:30:48 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      4/23/25 4:04:45 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

      Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE:JNJ) (the "Company") subsidiary Red River Talc LLC ("Red River") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants. Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these merit

      3/31/25 10:20:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care